StockNews.AI
CKPT
StockNews.AI
158 days

CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT

1. CKPT's proposed sale to Sun Pharmaceutical offers $4.10 per share plus contingencies. 2. An investigation is underway by KSF regarding the proposed sale transaction.

2m saved
Insight
Article

FAQ

Why Bullish?

The proposed sale price is higher than CKPT's recent trading prices, implying potential gains for investors.

How important is it?

The investigation indicates potential issues; however, the sale price itself is favorable overall.

Why Short Term?

The unfolding of the sale process and subsequent shareholder reactions will likely manifest quickly.

Related Companies

SUNPHGILDAVTX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkpoint Therapeutics, Inc. (NasdaqCM: CKPT) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Checkpoint will receive $4.10 per share and a contingent value right for up to $0.70 per share on achievement of a milestone. KSF is seeking to determ.

Related News